New drug guselkumab tested for Crohn's safety
Disease control
Completed
This study tested the safety of guselkumab in 38 people with moderately to severely active Crohn's disease. Participants received the drug first through an IV and then as injections. The main goal was to track side effects, including infections and injection reactions. This is a …
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC